Subscribe
shutterstock_121153783_sahara_prince
Sahara Prince / Shutterstock.com
5 July 2021Big PharmaAlex Baldwin

Five minutes with… Dmitry Karshtedt

Genus claims—or patent claims covering a family of related compounds—are commonplace in life sciences patent law. But following a rising trend of invalidity rulings, the future of the claim seems bleak.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

article
Five minutes with… Jacqueline Mulryne
26 November 2020   The partner at Arnold & Porter Kaye Scholer on second medical use patents, career goals after parenthood and the joy of being a “failed scientist” in IP.
Biotechnology
Five minutes with… Penny Gilbert
9 March 2021   The fallout from the landmark Regeneron v Kymab is still being weighed by the UK life sciences community.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

article
Five minutes with… Jacqueline Mulryne
26 November 2020   The partner at Arnold & Porter Kaye Scholer on second medical use patents, career goals after parenthood and the joy of being a “failed scientist” in IP.
Biotechnology
Five minutes with… Penny Gilbert
9 March 2021   The fallout from the landmark Regeneron v Kymab is still being weighed by the UK life sciences community.

More on this story

article
Five minutes with… Jacqueline Mulryne
26 November 2020   The partner at Arnold & Porter Kaye Scholer on second medical use patents, career goals after parenthood and the joy of being a “failed scientist” in IP.
Biotechnology
Five minutes with… Penny Gilbert
9 March 2021   The fallout from the landmark Regeneron v Kymab is still being weighed by the UK life sciences community.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent